The powersports and recreational watercraft industries are experiencing a notable upswing, driven by consumers’ growing appetite for outdoor adventures and leisure activities. Amid this surge, Massimo (NASDAQ: MAMO), a Texas-based manufacturer and distributor, is emerging as a significant player, capitalizing on … Continue reading →

NextPlat (NASDAQ: NXPL, NXPLW) reported Q1 2025 revenue of $14.5 million, down from $17.5 million in the prior year, driven by changes in 340B pharmacy agreements and prescription volume. Gross margin declined to 23.8%, while operating expenses fell 26% to $4.9 … Continue reading →

Massimo (NASDAQ: MAMO) is entering a new growth phase with the launch of a comprehensive digital retail platform. This move, announced in April 2025, is designed to simplify the purchasing process for its UTVs, ATVs, and mini-bikes, while expanding the … Continue reading →

HeartBeam (NASDAQ: BEAT) reported Q1 2025 results highlighted by successful completion of the VALID-ECG pivotal study, supporting its 510(k) submission for 12-lead ECG synthesis software and confirming productive ongoing FDA discussions. The company launched an Early Access Program, signed a strategic … Continue reading →

Ucore Rare Metals (TSXV: UCU) (OTCQX: UURAF) is nearing the commissioning of its RapidSX(TM) Commercial Demonstration Plant in Kingston, Ontario, a key milestone in its plan to commercialize its advanced rare earth element (REE) separation technology. The company is also preparing … Continue reading →

FAVO Capital (OTC: FAVO), a private credit firm focused on merchant cash advances and revenue-based financing for underserved SMBs, announced the voluntary conversion of all outstanding Super Voting Series C Preferred Shares into common stock. The move simplifies the company’s capital … Continue reading →

As the opioid crisis continues to challenge public health systems, the need for innovative solutions has become increasingly apparent. Rather than relying solely on restrictive measures, companies such as Nutriband (NASDAQ: NTRB) are exploring technological advancements to mitigate abuse while ensuring patient … Continue reading →

Intelligent Bio Solutions (Nasdaq: INBS), a medical technology company delivering rapid, non-invasive testing solutions, reported a 20% sequential revenue increase to $728,867 in fiscal Q3 2025, driven by growth in cartridge sales, which now account for 58% of total revenue … Continue reading →

CNS Pharmaceuticals (NASDAQ: CNSP) announced the successful transfer of Orphan Drug Designation from Cortice Biosciences for its lead asset TPI 287, covering gliomas, pediatric neuroblastoma, and progressive supranuclear palsy. TPI 287, a microtubule-stabilizing abeotaxane, has shown potential to cross the … Continue reading →

NRx Pharmaceuticals (NASDAQ: NRXP) announced that its wholly owned subsidiary, HOPE Therapeutics(TM), has signed a definitive agreement to acquire the Kadima Neuropsychiatry Institute. Kadima, a leading California clinic for interventional psychiatry, offers treatments such as ketamine, Spravato, transcranial magnetic stimulation … Continue reading →

Disseminated on behalf of SolarBank Corporation SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the U.S., has announced a … Continue reading →

Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) is a critical metals (“CM”) separation technology company executing an ESG-centered plan toward establishing a comprehensive North American critical metals supply chain. The company has developed a transformative commercial-ready technology, RapidSX(TM), for separating and purifying critical metals. … Continue reading →